Swallowing Safety
Penetration–aspiration events of concern (i.e., at least one PAS score ≥ 3) were found in nine of 12 participants in the oropharyngeal cancer cohort and in one healthy control (Wald χ2 = 7.99, p < .02, OR = 33, 95% CI [2.9, 371.31]). Incomplete LVC was found in six of 12 participants in the OPC cohort and in one healthy control (Wald χ2 = 5.27, p = .07, OR = 11, 95% CI [1.06, 114.09]). We found a statistically significant association between safe/impaired PAS scores and LVC integrity as assessed by Fisher's exact test (p < .001). Of the swallows displaying impaired safety (n = 10), seven (70%) occurred in the context of incomplete LVC; by contrast, LVC was documented as complete in 100% of safe swallows. Individuals with complete LVC had dramatically lower odds (OR = 0.18, 95% CI [0.06, 0.5]) of a PAS score of concern.
Descriptive statistics for parameters related to swallowing safety are summarized by group in
Table 3. Time-to-LVC was significantly longer in the OPC patients compared to the healthy controls,
F(1, 21) = 20.074,
p < .0001. Post hoc Sidak tests were conducted between three subgroups within the data: healthy participants, OPC participants with PAS scores of < 3 (
n = 3), and OPC participants with PAS of ≥ 3 (
n = 9). Group differences are illustrated in
Figure 1. Time-to-LVC for the OPC safe swallows did not differ significantly from the healthy control swallows (
p = .319) or from the OPC swallows with impaired safety (
p = .227). However, the pairwise difference between healthy participant swallows and the impaired OPC swallows was statistically significant (
p < .001) and had a large effect size (Cohen's
d = 2.16). No significant differences in LVCDur were found between participant groups.
Swallowing Efficiency
The oropharyngeal cancer group had a mean total residue measurement of 2.9% (C2–4)2 (95% CI [0.3%, 5.6%]) compared to a mean of 2.3% (95% CI [0.6%, 4.1%]) in the control group, H(1) = 0.014, p = .907. Pharyngeal residue of concern (i.e., > 3% (C2–4)2) was found in four of 12 oropharyngeal cancer participants. However, three of 12 healthy control participants also displayed residue above the 3% (C2–4)2 threshold. The frequency of above-threshold residue did not differ significantly between groups (Wald χ2 = 3.997, p = .136); however, the odds were higher in the oropharyngeal cancer group (OR = 1.5, 95% CI [0.25, 8.84]).
Descriptive statistics for parameters related to swallowing efficiency are summarized by group in
Table 4. The median for PhAR in the oropharyngeal cancer patients (53%) fell below the values seen in the healthy participants (
x̅ = 58%); however, this difference was not statistically significant,
H(1) = 1.76,
p = .184. A single participant in the entire data set, an oropharyngeal cancer patient, displayed unusually small PhAR below 36% of the (C2–4)
2 reference scalar. Interestingly, however, five of 12 oropharyngeal cancer patients (i.e., 42%) had PhAR below the first quartile boundary seen in healthy young participants (i.e., 47% of the (C2–4)
2 reference scalar) compared to zero of 12 participants in the healthy control group (Fisher's exact test,
p = .04,
OR = 1.714, 95% CI [1.06, 2.77]). The analyses did not reveal any apparent relationship between small PhAR measures (< 47% (C2–4)
2) and above-normal total residue (Fisher's exact test,
p = 1.0).
The median PhAMPC for the oropharyngeal cancer participants measured 2.4% of the (C2–4)
2 space (first quartile: 0%, third quartile: 7.6%), compared to median values in the healthy controls of 1.5% (first quartile: 0%, third quartile: 2%). The group difference in PhAMPC was not significant,
H(1) = 0.492,
p = .483. Of the 24 swallows in the data set, five (21%) displayed poor pharyngeal constriction (≥ 4% of (C2–4)
2); four of these five cases came from the oropharyngeal cancer cohort (Wald χ
2 = 7.08,
p < .01,
OR = 5.5, 95% CI [0.59, 59.01]). Overall, there was a strong, positive correlation between PhAMPC and the presence of residue,
rs (24) = .859,
p < .001, as illustrated in
Figure 2. When binary classifications of above-normal PhAMPC (i.e., ≥ 4% (C2–4)
2) were cross-tabulated with above-normal residue, a significantly greater proportion (80%) of the poor constriction cases displayed above-threshold residue (Fisher's exact test,
p < .05,
OR = 21.3, 95% CI [1.73, 263.67]). No significant differences were found between groups for measures of UES opening diameter,
F(1, 20) = 0.010,
p = .920, or duration,
F(1, 22) = 2.592,
p = .122, and there were no significant correlations between UES opening diameter and residue,
rs (24) = .155,
p = .492, or between UES opening duration and residue,
rs (24) = .369,
p = .076.